Krystal Biotech (KRYS) said Wednesday that preliminary results from its Kyanite-1 clinical trial showed "early evidence" of monotherapy activity that was mostly seen in participants with advanced non-small cell lung cancer.
The company is evaluating inhaled KB707, a modified HSV-1 vector, to treat solid tumors in the lung, it added.
The objective response rate in the trial was 27%, while the disease control rate was 73% as of Dec. 6, the company said.
Krystal Biotech said the first participant in the trial was dosed on April 17, while a total of 37 patients were enrolled who received at least one dosage of inhaled KB707, which has been "safe and generally well tolerated" to date.
Based on the initial results, Krystal Biotech said it has amended the Kyanite-1 protocol to include two groups evaluating inhaled KB707 in combination with either anti-programmed cell death protein 1 therapy or anti-PD-1 therapy and chemotherapy.
Shares of the company rose 4.4% in recent Wednesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。